U.S. 100% Pharmaceutical Tariffs Take Effect, Small and Mid-Cap Biotech Companies Under Pressure
nashnova research
A 100% tariff on select patented drugs and active ingredients took effect Tuesday, hitting over a hundred small and mid-sized biotech firms that rely heavily on overseas contract manufacturing — the industry warns R&D budgets face serious erosion.
Why does this round single out smaller companies?
Phase-one tariffs hit big pharma in late July. This round targets smaller firms with fewer resources and deeper dependence on offshore contract manufacturers.
Brookings senior fellow Marta Wosińska estimates over 100 companies still have products subject to the tariff — and many lack the capacity to move production stateside.
This means → some of these firms own no manufacturing facilities at all, relying entirely on contract producers in India, Singapore, and other pharma hubs. The tariff lands on their most vulnerable link.
Exemption paths exist — but can small firms reach them?
The Commerce Department offers two tiers: companies that sign a "most-favored-nation" drug-pricing deal and commit to reshoring get a three-year tariff exemption; those committing only to reshoring pay 20% until 2030.
Nine categories of specialty drugs from jurisdictions with U.S. trade agreements — the EU, UK, Switzerland, Japan, South Korea — are also exempt, as are products that demonstrate an urgent public-health need.
In plain terms = the exemption menu looks broad, but when Commerce will decide, how it defines "urgent need," and whether tariffs paid during review can be refunded — none of that has a clear answer.
What happens to firms that cannot reshore?
Wosińska notes: "If they can't do it, the easier path may be to merge with a larger pharma company or sell off product lines."
This means → the tariff is effectively forcing a binary choice on small biotechs: spend heavily to build U.S. capacity, or consolidate under a bigger roof.
Partnering with domestic contract manufacturers is a viable middle path, but building new facilities and hiring staff is costly — not an easy lift for cash-constrained firms.
What does draining R&D funding really signal?
The Biotechnology Innovation Organization (BIO) says the tariffs "reverse decades of sound trade policy and create new uncertainty for biotech innovators."
BIO CEO John Crowley urged the administration this month to repeal the tariffs or grant broad exemptions, citing "inconsistent and unpredictable decisions" that could harm patient access to medicines.
This reflects a deeper signal: tariff pressure will ultimately distribute across M&A consolidation, R&D contraction, and price pass-through — the split among those three paths is the key variable to watch over the coming quarters.
市场有风险，内容仅供研究参考，不构成投资建议。